Aclaris Therapeutics vs Dianthus Therapeutics
Aclaris Therapeutics reported revenue of $8 million in fiscal 2025, 3.9 times Dianthus Therapeutics' $2 million in fiscal 2025. Aclaris Therapeutics' revenue fell 58.2% in its latest year, and Dianthus Therapeutics' fell 67.3%. Aclaris Therapeutics had an operating margin of -975.9%, against -8739.3% at Dianthus Therapeutics. Free cash flow was −$47 million at Aclaris Therapeutics and −$129 million at Dianthus Therapeutics.
Side by side
| Aclaris Therapeutics | Dianthus Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $8M | $2M |
| Revenue growth | −58.2% | −67.3% |
| Revenue growth a year, last 5 years | 3.7% | — |
| Gross margin | 73.3% | — |
| Operating margin | −975.9% | −8,739.3% |
| Net margin | −829.6% | −7,973.3% |
| Free cash flow | −$47M | −$129M |
| Free cash flow margin | −603.4% | −6,349.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 58.6% | 15.9% |
| Last close | $3.92 | $91.81 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $79.2 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aclaris TherapeuticsDianthus Therapeutics
Operating margin
Percent of revenue
Aclaris TherapeuticsDianthus Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aclaris TherapeuticsDianthus Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aclaris Therapeutics and Dianthus Therapeutics pages.